Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis

a single-arm, single-center, clinical trial

Ryota Sakai, Tsuneo Kondo, Jun Kikuchi, Akiko Shibata, Kentaro Chino, Ayumi Okuyama, Hirofumi Takei, Koichi Amano

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: To assess the efficacy of tocilizumab (TCZ) monotherapy for the remission induction of microscopic polyangiitis (MPA) in a prospective single-arm, single-center, cohort, pilot study. Methods: Eligible patients were aged between 20 and 80 years and were newly diagnosed with MPA according to Watts’ classification algorithm. Seven patients received 8 mg/kg of intravenous TCZ fortnightly for the first 2 months (5 courses), and monthly for the next 10 months (10 courses). One year after TCZ monotherapy, the patients were followed-up without any treatment. The protocol did not permit the use corticosteroids or any other immunosuppressants. Complete remission (CR) was defined as the Birmingham Vasculitis Activity Score of 0 at two consecutive visits made at least a month apart. Results: CR was achieved in two of six patients (33.3%) at 6 months and three patients (50.0%) at 12 months. Two patients were withdrawn: one because of inefficacy at 6 weeks and the other because of flare at 6 months. One patient voluntarily withdrew after CR at 3 months. Four patients (66.7%) could be kept drug-free after 1 year of TCZ without relapse for 6–15 months at the last visit. Conclusion: TCZ monotherapy may be an alternative treatment strategy in some patients with MPA.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - 2016 Apr 6
Externally publishedYes

Fingerprint

Microscopic Polyangiitis
Adrenal Cortex Hormones
Clinical Trials
Therapeutics
tocilizumab
Remission Induction
Immunosuppressive Agents
Vasculitis
Cohort Studies

Keywords

  • Antineutrophil cytoplasmic antibody
  • Microscopic polyangiitis
  • Tocilizumab
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis : a single-arm, single-center, clinical trial. / Sakai, Ryota; Kondo, Tsuneo; Kikuchi, Jun; Shibata, Akiko; Chino, Kentaro; Okuyama, Ayumi; Takei, Hirofumi; Amano, Koichi.

In: Modern Rheumatology, 06.04.2016, p. 1-8.

Research output: Contribution to journalArticle

Sakai, Ryota ; Kondo, Tsuneo ; Kikuchi, Jun ; Shibata, Akiko ; Chino, Kentaro ; Okuyama, Ayumi ; Takei, Hirofumi ; Amano, Koichi. / Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis : a single-arm, single-center, clinical trial. In: Modern Rheumatology. 2016 ; pp. 1-8.
@article{4fb6f21eec8c4491804b2f08267db55b,
title = "Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial",
abstract = "Objectives: To assess the efficacy of tocilizumab (TCZ) monotherapy for the remission induction of microscopic polyangiitis (MPA) in a prospective single-arm, single-center, cohort, pilot study. Methods: Eligible patients were aged between 20 and 80 years and were newly diagnosed with MPA according to Watts’ classification algorithm. Seven patients received 8 mg/kg of intravenous TCZ fortnightly for the first 2 months (5 courses), and monthly for the next 10 months (10 courses). One year after TCZ monotherapy, the patients were followed-up without any treatment. The protocol did not permit the use corticosteroids or any other immunosuppressants. Complete remission (CR) was defined as the Birmingham Vasculitis Activity Score of 0 at two consecutive visits made at least a month apart. Results: CR was achieved in two of six patients (33.3{\%}) at 6 months and three patients (50.0{\%}) at 12 months. Two patients were withdrawn: one because of inefficacy at 6 weeks and the other because of flare at 6 months. One patient voluntarily withdrew after CR at 3 months. Four patients (66.7{\%}) could be kept drug-free after 1 year of TCZ without relapse for 6–15 months at the last visit. Conclusion: TCZ monotherapy may be an alternative treatment strategy in some patients with MPA.",
keywords = "Antineutrophil cytoplasmic antibody, Microscopic polyangiitis, Tocilizumab, Vasculitis",
author = "Ryota Sakai and Tsuneo Kondo and Jun Kikuchi and Akiko Shibata and Kentaro Chino and Ayumi Okuyama and Hirofumi Takei and Koichi Amano",
year = "2016",
month = "4",
day = "6",
doi = "10.3109/14397595.2016.1160968",
language = "English",
pages = "1--8",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis

T2 - a single-arm, single-center, clinical trial

AU - Sakai, Ryota

AU - Kondo, Tsuneo

AU - Kikuchi, Jun

AU - Shibata, Akiko

AU - Chino, Kentaro

AU - Okuyama, Ayumi

AU - Takei, Hirofumi

AU - Amano, Koichi

PY - 2016/4/6

Y1 - 2016/4/6

N2 - Objectives: To assess the efficacy of tocilizumab (TCZ) monotherapy for the remission induction of microscopic polyangiitis (MPA) in a prospective single-arm, single-center, cohort, pilot study. Methods: Eligible patients were aged between 20 and 80 years and were newly diagnosed with MPA according to Watts’ classification algorithm. Seven patients received 8 mg/kg of intravenous TCZ fortnightly for the first 2 months (5 courses), and monthly for the next 10 months (10 courses). One year after TCZ monotherapy, the patients were followed-up without any treatment. The protocol did not permit the use corticosteroids or any other immunosuppressants. Complete remission (CR) was defined as the Birmingham Vasculitis Activity Score of 0 at two consecutive visits made at least a month apart. Results: CR was achieved in two of six patients (33.3%) at 6 months and three patients (50.0%) at 12 months. Two patients were withdrawn: one because of inefficacy at 6 weeks and the other because of flare at 6 months. One patient voluntarily withdrew after CR at 3 months. Four patients (66.7%) could be kept drug-free after 1 year of TCZ without relapse for 6–15 months at the last visit. Conclusion: TCZ monotherapy may be an alternative treatment strategy in some patients with MPA.

AB - Objectives: To assess the efficacy of tocilizumab (TCZ) monotherapy for the remission induction of microscopic polyangiitis (MPA) in a prospective single-arm, single-center, cohort, pilot study. Methods: Eligible patients were aged between 20 and 80 years and were newly diagnosed with MPA according to Watts’ classification algorithm. Seven patients received 8 mg/kg of intravenous TCZ fortnightly for the first 2 months (5 courses), and monthly for the next 10 months (10 courses). One year after TCZ monotherapy, the patients were followed-up without any treatment. The protocol did not permit the use corticosteroids or any other immunosuppressants. Complete remission (CR) was defined as the Birmingham Vasculitis Activity Score of 0 at two consecutive visits made at least a month apart. Results: CR was achieved in two of six patients (33.3%) at 6 months and three patients (50.0%) at 12 months. Two patients were withdrawn: one because of inefficacy at 6 weeks and the other because of flare at 6 months. One patient voluntarily withdrew after CR at 3 months. Four patients (66.7%) could be kept drug-free after 1 year of TCZ without relapse for 6–15 months at the last visit. Conclusion: TCZ monotherapy may be an alternative treatment strategy in some patients with MPA.

KW - Antineutrophil cytoplasmic antibody

KW - Microscopic polyangiitis

KW - Tocilizumab

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=84964490790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964490790&partnerID=8YFLogxK

U2 - 10.3109/14397595.2016.1160968

DO - 10.3109/14397595.2016.1160968

M3 - Article

SP - 1

EP - 8

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -